Osawa Takahiro, Abe Takashige, Shinohara Nobuo, Harabayashi Toru, Sazawa Ataru, Kubota Kanako, Matsuno Yoshihiro, Shibata Takeshi, Shinno Yuichiro, Kamota Shinji, Minami Keita, Sakashita Shigeo, Kumagai Akira, Mori Tatsuya, Nonomura Katsuya
Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan.
Int J Urol. 2009 Mar;16(3):274-8; discussion 278. doi: 10.1111/j.1442-2042.2008.02221.x. Epub 2008 Dec 12.
To evaluate the prognostic role of different clinico-pathological parameters in node-positive patients treated by radical cystectomy.
A retrospective multi-institutional study of 435 patients who underwent radical cystectomy between 1990 and 2005 was carried out. Of them, pathological lymph node (LN) metastases were found in 83 patients. Sixty of these 83 patients, whose clinical information and follow-up data were available, were included in the analysis. Twenty-five patients had undergone adjuvant chemotherapy, whereas 35 had not. A Cox proportional hazards model was used to determine the impact of the following clinico-pathological parameters on patient survival: number of resected LNs, number of positive LNs, LN density (defined as the ratio of the number of positive LNs divided by the total number of resected LNs) and adjuvant chemotherapy.
Median follow-up for surviving patients was 41 months (range 4-138) after surgery. The median survival time for all patients was 22 months (95% confidence interval, 15-42 months). At multivariate analysis, LN density of 25% or less, adjuvant chemotherapy and pure urothelial carcinoma were independently significant predictors of survival.
Lymph node density predicts survival in patients with node-positive bladder cancer.
评估不同临床病理参数在接受根治性膀胱切除术的淋巴结阳性患者中的预后作用。
对1990年至2005年间接受根治性膀胱切除术的435例患者进行了一项回顾性多机构研究。其中,83例患者发现有病理淋巴结(LN)转移。这83例患者中有60例具备临床信息和随访数据,被纳入分析。25例患者接受了辅助化疗,而35例未接受。采用Cox比例风险模型来确定以下临床病理参数对患者生存的影响:切除的LN数量、阳性LN数量、LN密度(定义为阳性LN数量除以切除的LN总数的比值)以及辅助化疗。
存活患者术后的中位随访时间为41个月(范围4 - 138个月)。所有患者的中位生存时间为22个月(95%置信区间,15 - 42个月)。在多变量分析中,LN密度为25%或更低、辅助化疗以及单纯尿路上皮癌是生存的独立显著预测因素。
淋巴结密度可预测淋巴结阳性膀胱癌患者的生存情况。